Kaken Pharmaceutical Co Ltd banner
K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 115 JPY -1.2%
Market Cap: ¥155.8B

P/B

1.1
Current
9%
More Expensive
vs 3-y average of 1

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.1
=
Market Cap
¥165.7B
/
Total Equity
¥145.8B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.1
=
Market Cap
¥165.7B
/
Total Equity
¥145.8B

Valuation Scenarios

Kaken Pharmaceutical Co Ltd is trading above its 3-year average

If P/B returns to its 3-Year Average (1), the stock would be worth ¥3 765.21 (9% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-9%
Maximum Upside
+49%
Average Upside
17%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 1.1 ¥4 115
0%
3-Year Average 1 ¥3 765.21
-9%
5-Year Average 1 ¥3 939.37
-4%
Industry Average 1.6 ¥6 115.1
+49%
Country Average 1.4 ¥5 441.29
+32%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
JP
Kaken Pharmaceutical Co Ltd
TSE:4521
155.8B JPY 1.1 -40.7
US
Eli Lilly and Co
NYSE:LLY
867B USD 32.7 42
US
Johnson & Johnson
NYSE:JNJ
555.4B USD 6.8 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 7.7 20.1
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 5.9 28.2
CH
Novartis AG
SIX:NOVN
223.1B CHF 6 19.7
US
Merck & Co Inc
NYSE:MRK
283.6B USD 5.4 15.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD -58.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 5.6 10.6
US
Pfizer Inc
NYSE:PFE
151.6B USD 1.8 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
118.8B USD 6.4 16.8
P/E Multiple
Earnings Growth PEG
JP
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Average P/E: 22.1
Negative Multiple: -40.7
-49%
N/A
US
Eli Lilly and Co
NYSE:LLY
42
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.4
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28.2
25%
1.1
CH
Novartis AG
SIX:NOVN
19.7
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1

Market Distribution

Lower than 70% of companies in Japan
Percentile
30th
Based on 5 195 companies
30th percentile
1.1
Low
0 — 1.1
Typical Range
1.1 — 2.1
High
2.1 —
Distribution Statistics
Japan
Min 0
30th Percentile 1.1
Median 1.4
70th Percentile 2.1
Max 31 732 017.6

Kaken Pharmaceutical Co Ltd
Glance View

Market Cap
155.8B JPY
Industry
Pharmaceuticals

Founded in 1948, Kaken Pharmaceutical Co., Ltd. is a prominent player in Japan's pharmaceutical landscape, seamlessly blending tradition with innovation. The company's journey began amidst post-war economic rebuilding, initially catering to the nation's healthcare needs with basic medicines. Over the years, it has carved out a niche for itself, specializing in the development, manufacturing, and commercialization of a wide range of pharmaceutical products. Kaken's focus areas include dermatology, orthopedics, and surgery, with a strong emphasis on treatments for fungal infections and inflammation management. This specialization has propelled the company into a position of leadership, especially in the dermatology market, where its expertise in topical formulations excels. Kaken Pharmaceutical monetizes its ventures primarily through the sale of prescription and over-the-counter drugs, leveraging a robust distribution network that extends its reach across Japan and international markets. The company continually reinvests in research and development to sustain its competitive edge, regularly introducing innovative therapies that address unmet medical needs. While pharmaceuticals remain its core revenue stream, Kaken also generates income from its chemical businesses, which include agrochemicals and animal health products, further diversifying its portfolio. By maintaining a balanced blend of traditional pharmaceutical sales and chemical product lines, Kaken ensures steady financial footing while advancing health solutions for a global audience.

Intrinsic Value
3 343.71 JPY
Overvaluation 19%
Intrinsic Value
Price ¥4 115
K
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett